TriCore Welcomes Jesse Young, PhD as Medical Director at TriCore Research Institute
October 11, 2022
TriCore Media Contact:
Director, Organizational Development & Communications
TRICORE WELCOMES JESSE YOUNG, PhD AS MEDICAL DIRECTOR AT
TRICORE RESEARCH INSTITUTE
FOR IMMEDIATE RELEASE – October 11, 2022 – ALBUQUERQUE, NEW MEXICO – TriCore Research Institute (TRI), the dedicated research division of TriCore, welcomes Dr. Jesse Young as a medical director. In his role, he will promote quality and ensure fiscal and regulatory compliance for our research and diagnostic device trial partners. He will produce scholarly works by publishing in peer-reviewed journals and abstracts, and present at scientific and clinical conferences. Dr. Young has ten years’ experience in infectious disease, including 2-years working at TriCore in the Clinical Device Trials Department.
“His skills, expertise and enthusiasm for the work done at the TriCore Research Institute are pivotal in these challenging times, said Veronica, Luzzi, PhD, TRI Medical Director. “He will help us secure a vibrant future for TRI and the rest of the TriCore enterprise.”
Dr. Young is a native New Mexican and graduated with a Ph.D. from the Biomedical Sciences Graduate Program (BSGP) at the University of New Mexico (UNM) School of Medicine. While pursuing his PhD in Michelle Ozbun’s Lab, he researched protamine sulfate, a drug that was repurposed as a prophylactic to block HPV infection by preventing viral binding to host cells. His dissertation focused on the dynamics of HPV infections, specifically targeting the molecular mechanisms that promote HPV binding and internalization.
During his post doctorate in Dr. Darrell Dinwiddie’s Lab at UNM, Dr. Young participated in the NIH SARS-CoV-2 Surveillance Collaborative between UNM, TriCore, and the New Mexico State Scientific Laboratory Division performing sequencing on SARS-CoV-2 variants. He was directly involved in the identification of the Omicron variant in New Mexico. Dr. Young also worked as a collaborator with the TRI Clinical Trials Department to perform sequence validation for Federal Drug Administration (FDA) Emergency Use Authorizations (EUAs) for over-the-counter COVID-19 tests.
TriCore Research Institute (TRI) is the dedicated research division of TriCore, an independent, not-for-profit clinical laboratory founded and headquartered in Albuquerque, NM. TRI brings TriCore’s scientific and academic expertise to deliver contract research for clinical and in-vitro diagnostic device trials, an extensive biorepository and central laboratory services to healthcare and scientific organizations worldwide. For more information, visit tricore.org.